James McCullough | executive |
Howard Doran | executive |
Thomas McLain | executive |
Oliver Sterling | executive |
Mark Massaro | analyst |
Paul Stewardson | analyst |
Randy Baron | analyst |
Jens Lindqvist | analyst |
Good morning, ladies and gentlemen, and welcome to the Renalytix conference call to review first quarter fiscal year 2024 financial results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.I would now like to turn the call over to Peter DeNardo of CapComm Partners for a few introductory comments.
Thank you, Libya. Thank you, all, for participating in today's call.
Joining me today from Renalytix to provide formal remarks are James McCullough, Chief Executive Officer; Howard Doran, Chief Business Officer; Tom McLain, President; and James Sterling, Chief Financial Officer.Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.